Showing 2021-2030 of 2165 results for "".
- Vision 2020 USA to Hold Annual World Sight Day Briefing on October 17, 2019https://modernod.com/news/vision-2020-usa-to-hold-annual-world-sight-day-briefing-on-october-17-2019/2476939/As part of World Sight Day events, on Oct. 17, 2019, Vision 2020 USA will be holding an educational luncheon briefing at the Rayburn House Office Building, 2075, in aWashington DC, from noon to 1 p.m. According to Prevent Blindness, by 2050, the impaired and blind populations are projecte
- European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10https://modernod.com/news/european-medicines-agency-grants-prime-access-to-proqrs-sepofarsen-for-lebers-congenital-amaurosis-10/2476779/ProQR Therapeutics announced that its sepofarsen (QR-110) drug candidate, which is being developed for targeting the p.Cys998X mutation in the CEP290 gene for the treatment of Leber’s congenital amaurosis 10 (LCA10), was granted access to the Priority Medicines (PRIME) program by the European Med
- Tilak Healthcare Announces Exclusive Partnership for Co-Promotion with Novartis Francehttps://modernod.com/news/tilak-healthcare-announces-exclusive-partnership-for-co-promotion-with-novartis-france/2476578/Tilak Healthcare, a video game studio specializing in mobile medical games for patients with chronic diseases, announced an exclusive co-promotion partnership with Novartis France for OdySight, its first clinically validated mobile game to monitor vision remotely. Tilak He
- ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-reaches-agreement-with-the-fda-on-design-of-phase-2-3-pivotal-trial-for-sepofarsen-qr-110-for-lebers-congenital-amaurosis-10/2476214/ProQR Therapeutics announced that it has reached agreement with the FDA on the design of a phase 2/3 pivotal trial (ILLUMINATE) for QR-110, now renamed to sepofarsen, in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290gene. LCA is the lead
- OWL to Host Signature Event and Awards Ceremony at AAO 2018https://modernod.com/news/owl-to-host-signature-event-and-awards-ceremony-at-aao-2018/2479767/OWL: Advancing Diversity in Leadership (OWL) announced that it will host its annual OWL Signature Event and Awards Ceremony at the American Academy of Ophthalmology (AAO). OWL’s largest event of the year will take place on Sunday, October 28, 2018 from 5:30-7:00 p.m., at Revel Motor Row in Chicag
- Jeffrey Krallhttps://modernod.com/profiles/jeffrey-krall/OnmPMz/
- Jeffrey Augustinehttps://modernod.com/profiles/jeffrey-augustine/L0aDdG/
- Jeffrey Sonsinohttps://modernod.com/profiles/jeffrey-sonsino/j3er55/
- Jeffrey Lewishttps://modernod.com/profiles/jeffrey-lewis/OEAwyO/
- Eris P. Jordanhttps://modernod.com/profiles/eris-p-jordan/jJ3xwe/